Imago BioSciences expands myelofibrosis drug trial into Hong Kong,

Biotechnology company Imago BioSciences has expanded its global Phase IIb clinical study evaluating bomedemstat (IMG-7289) into Hong Kong., Biotechnology company Imago BioSciences has expanded its global Phase IIb clinical study evaluating bomedemstat (IMG-7289) into Hong Kong., Read More

Scroll to Top